GleamWall
中文EN

CLDI Calidi Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.74M$8.88M
SG&A expense$10.50M$12.90M
Operating income-$20.24M-$21.78M
Interest expense$100,000$700,000
Pretax income-$20.05M-$22.20M
Income tax$15,000$14,000
Net income-$19.91M-$22.14M
EBITDA-$18.59M-$20.24M
EPS (basic)-5.95-35.70
EPS (diluted)-5.95-35.70
Weighted avg. shares (diluted)4,302667
Balance sheet
Cash & equivalents$5.82M$9.81M
Current assets$6.26M$10.23M
PP&E, net$781,000$869,000
Total assets$8.86M$14.18M
Current liabilities$3.94M$9.50M
Short-term debt$90,000$3.22M
Long-term debt$600,000$600,000
Total debt$690,000$3.82M
Total liabilities$5.10M$12.21M
Shareholders' equity$3.76M$1.53M
Net debt-$5.13M-$5.99M
Shares outstanding451,0761.73M
Cash flow statement
Operating cash flow-$21.29M-$19.69M
Investing cash flow-$170,000-$16,000
Financing cash flow$17.46M$27.36M
Depreciation & amortization$1.65M$1.53M
Stock-based compensation$2.11M$2.96M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.